Janux Therapeutics
Janux Therapeutics is a clinical-stage biotechnology company specializing in developing tumor-activated T cell immunotherapies for cancer, with ongoing Phase 1 trials and a significant collaboration with Merck.
Company Overview
Janux Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, California. The company specializes in developing tumor-activated T cell immunotherapies aimed at treating cancer. Its primary mission is to overcome traditional T cell engager toxicity and efficacy limitations through its innovative technology platform.
Technology Platform
Janux Therapeutics utilizes an advanced technology platform designed to address the challenges faced by traditional T cell engagers. These include toxicity and efficacy limitations, which the company aims to overcome through its specialized approach. The platform is at the core of Janux's mission to develop safer and more effective cancer treatments.
Clinical Programs
Janux Therapeutics is conducting Phase 1 clinical trials for its leading programs, PSMAxCD3-TRACTr JANX007 and EGFRxCD3-TRACTr JANX008. These programs target Prostate-Specific Membrane Antigen (PSMA) and Epidermal Growth Factor Receptor (EGFR), respectively, as part of the company's broader effort to develop targeted cancer immunotherapies.
Financial Milestones
In its financial journey, Janux Therapeutics has successfully raised $296.5 million through a public offering of common stock and pre-funded warrants. This substantial funding enables the company to advance its research and development activities, including ongoing clinical trials and future projects.
Research Collaborations
Janux Therapeutics engages in significant research collaborations to strengthen its technological and therapeutic capabilities. Notably, the company has an exclusive license agreement with Merck, underlining its collaborative approach to advancing cancer treatment options.